Drug Profile
Pralsetinib - Blueprint Medicines
Alternative Names: BLU-667; CS 3009; GAVRETO; Gavreto; Pratinib; Pujihua; RG 6396Latest Information Update: 17 Apr 2024
Price :
$50
*
At a glance
- Originator Blueprint Medicines
- Developer Blueprint Medicines; CStone Pharmaceuticals; Roche
- Class Amides; Amines; Antineoplastics; Cyclohexanes; Ethers; Fluorinated hydrocarbons; Pyrazoles; Pyridines; Pyrimidines; Small molecules
- Mechanism of Action Proto oncogene protein c ret inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Non-small cell lung cancer; Thyroid cancer
- Phase II Solid tumours
Most Recent Events
- 21 Mar 2024 Hoffmann-La Roche completes a phase I/II ARROW trial for Solid tumours (Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) the US, Belgium, China, France, Germany, Hong-Kong, Italy, South Korea, Netherland, Singapore, Spain, Taiwan, the United Kingdom (PO) (NCT03037385) (EudraCT2016-004390-41)
- 21 Mar 2024 Hoffmann-La Roche completes a phase I/II ARROW trial for Thyroid cancer (Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater, First-line therapy) in the US, Belgium, China, France, Germany, Hong-Kong, Italy, South Korea, Netherland, Singapore, Spain, Taiwan, the United Kingdom (PO) (NCT03037385) (EudraCT2016-004390-41)
- 21 Mar 2024 Hoffmann-La Roche completes a phase I/II ARROW trial for Non-small cell lung cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in the US, Belgium, China, France, Germany, Hong-Kong, Italy, South Korea, Netherland, Singapore, Spain, Taiwan, the United Kingdom (PO)(NCT03037385) (EudraCT2016-004390-41)